Advertisement
Australia markets closed

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • AUD/USD

    0.6528
    +0.0028 (+0.43%)
     

  • OIL

    82.66
    -0.15 (-0.18%)
     

  • GOLD

    2,338.40
    0.00 (0.00%)
     

  • Bitcoin AUD

    97,859.39
    -3,780.17 (-3.72%)
     

  • CMC Crypto 200

    1,362.73
    -19.85 (-1.44%)
     

  • AUD/EUR

    0.6084
    +0.0014 (+0.23%)
     

  • AUD/NZD

    1.0954
    +0.0012 (+0.11%)
     

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     

  • FTSE

    8,089.90
    +49.52 (+0.62%)
     

  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     

  • DAX

    17,981.55
    -107.15 (-0.59%)
     

  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

Lumos Pharma to Participate in Upcoming Investor Conferences

Lumos Pharma, Inc.
·2-min read

AUSTIN, Texas, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the following upcoming investor conferences:

Event:

Stifel 2021 Virtual Healthcare Conference – November 16th - 17th

Presentation:

Presentation November 16th from 3:20-3:50 PM EST

1x1 Meetings:

Virtual one-on-one meetings with management November 16th throughout the day

Webcast link:

Here


Event:

Jefferies London Healthcare Conference – November 16th - 19th

Presentation:

Pre-recorded fireside chat available beginning November 18th at 8:00 AM GMT / 3:00 AM EST

1x1 Meetings:

One-on-one meetings with management to be held November 18th & 19th throughout each day

Webcast link:

Here


Event:

Piper Sandler 33rd Annual Virtual Healthcare Conference – November 30th - December 2nd

Presentation:

Pre-recorded fireside chat available beginning November 22nd at 10:00 AM EST

1x1 Meetings:

One-on-one meetings with management to be held December 1st throughout the day

Webcast link:

Available on Lumos Pharma’s website (here) as of November 22nd at 10:00 AM EST


To schedule a meeting with management during the conferences, please contact your salesperson at the respective firm. Webcasts for each presentation will be available on the Company’s website under “Events & Presentations” in the Investors & Media section.

ADVERTISEMENT

About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2 clinical trial, the OraGrowtH210 Trial, and a PK/PD trial, the OraGrowtH212 Trial, for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to recombinant growth hormone injections that PGHD patients otherwise endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.

Investor & Media Contact:

Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com

Source: Lumos Pharma, Inc.